Oosthuizen Johannes Jacobus 4

4 · Merck & Co., Inc. · Filed Feb 5, 2024

Form 4

Period: 2024-02-02

President, U.S. Market

Transactions

Exercise/Conversion
Common Stock
2024-02-02$75.36/sh+6,773$510,413→ 28,122.345 total
Exercise/Conversion
Common Stock
2024-02-02$87.10/sh+7,119$620,065→ 42,286.345 total
Sale
Common Stock
2024-02-02$127.17/sh−18,959$2,411,111→ 23,327.345 total
Exercise/Conversion
Stock Option (Right to Buy)
2024-02-02−7,045→ 7,049 total
Exercise: $73.73From: 2022-05-04Exp: 2031-05-03→ Common Stock (7,045 underlying)
Exercise/Conversion
Common Stock
2024-02-02$73.73/sh+7,045$519,428→ 35,167.345 total
Exercise/Conversion
Stock Option (Right to Buy)
2024-02-02−7,119→ 14,240 total
Exercise: $87.10From: 2023-05-03Exp: 2032-05-02→ Common Stock (7,119 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2024-02-02−6,773→ 0 total
Exercise: $75.36From: 2021-05-01Exp: 2030-04-30→ Common Stock (6,773 underlying)

Footnotes (4)

[F1]Holdings include shares acquired in dividend reinvestment transactions.
[F2]The option vested and became exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023.
[F3]The option vests and becomes exercisable in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024.
[F4]The option vests and becomes exercisable in three equal installments on 5/3/2023, 5/3/2024 and 5/3/2025.

Documents

1 file